Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Share-based Compensation (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Share-based Compensation for 16 consecutive years, with $5.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 9.48% year-over-year to $5.7 million, compared with a TTM value of $24.8 million through Dec 2025, up 11.36%, and an annual FY2025 reading of $24.8 million, up 11.36% over the prior year.
  • Share-based Compensation was $5.7 million for Q4 2025 at Catalyst Pharmaceuticals, roughly flat from $5.7 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $8.2 million in Q1 2024 and bottomed at $1.5 million in Q4 2021.
  • Average Share-based Compensation over 5 years is $3.8 million, with a median of $3.6 million recorded in 2023.
  • The sharpest move saw Share-based Compensation surged 185.2% in 2024, then dropped 29.07% in 2025.
  • Year by year, Share-based Compensation stood at $1.5 million in 2021, then soared by 30.84% to $1.9 million in 2022, then skyrocketed by 120.66% to $4.2 million in 2023, then grew by 21.67% to $5.2 million in 2024, then rose by 9.48% to $5.7 million in 2025.
  • Business Quant data shows Share-based Compensation for CPRX at $5.7 million in Q4 2025, $5.7 million in Q3 2025, and $7.6 million in Q2 2025.